Portal de Periódicos da CAPES

Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia

2018; Wiley; Volume: 84; Issue: 5 Linguagem: Inglês

10.1002/ana.25333

1531-8249

David Bergeron, Maria Luisa Gorno‐Tempini, Gil D. Rabinovici, Miguel A. Santos‐Santos, William W. Seeley, Bruce L. Miller, Yolande A.L. Pijnenburg, M. Antoinette Keulen, Colin Groot, Bart N.M. van Berckel, Wiesje M. van der Flier, Philip Scheltens, Jonathan D. Rohrer, Jason D. Warren, Jonathan M. Schott, Nick C. Fox, Raquel Sánchez‐Valle, Oriol Grau‐Rivera, Ellen Gelpí, Harro Seelaar, Janne M. Papma, John C. van Swieten, John R. Hodges, Cristian E. Leyton, Olivier Piguet, Emily Rogalskı, Marsel Mesulam, Lejla Koric, Nora Kristensen, Jeéreémie Pariente, Bradford C. Dickerson, Ian R. Mackenzie, Ging‐Yuek Robin Hsiung, Serge Belliard, David J. Irwin, David A. Wolk, Murray Grossman, Matthew Jones, Jennifer Harris, David Mann, Julie S. Snowden, Patricio Chrem-Méndez, Ismael Luis Calandri, Alejandra A. Amengual, Carole Miguet‐Alfonsi, Éloi Magnin, Giuseppe Magnani, Roberto Santangelo, Vincent Deramecourt, Florence Pasquier, Niklas Mattsson, Christer Nilsson, Oskar Hansson, Julia Keith, Mario Masellis, Sandra E. Black, Jordi A. Matías‐Guiu, María‐Nieves Cabrera‐Martin, Claire Paquet, Julien Dumurgier, Marc Teichmann, Marie Sarazin, Michel Bottlaender, Bruno Dubois, Christopher C. Rowe, Victor L. Villemagne, Rik Vandenberghe, Elias Granadillo, Edmond Teng, Mario F. Mendez, Philipp T. Meyer, Lars Frings, Alberto Lleó, Rafael Blesa, Juan Fortea, Sang Won Seo, Janine Diehl‐Schmid, Timo Grimmer, Kristian Steen Frederiksen, Pascual Sánchez‐Juan, Gaël Chételat, Willemijn J. Jansen, Rémi W. Bouchard, Robert Laforce, Pieter Jelle Visser, Rik Ossenkoppele,

Neurobiology of Language and Bilingualism

Objective To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants. Methods We conducted a meta‐analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid‐β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using generalized estimating equation models. Results Amyloid‐β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p < 0.001). Prevalence of amyloid‐β positivity increased with age in nfvPPA (from 10% at age 50 years to 27% at age 80 years, p < 0.01) and svPPA (from 6% at age 50 years to 32% at age 80 years, p < 0.001), but not in lvPPA ( p = 0.94). Across PPA variants, ApoE ε4 carriers were more often amyloid‐β positive (58.0%) than noncarriers (35.0%, p < 0.001). Autopsy data revealed Alzheimer disease pathology as the most common pathologic diagnosis in lvPPA (76%), frontotemporal lobar degeneration–TDP‐43 in svPPA (80%), and frontotemporal lobar degeneration–TDP‐43/tau in nfvPPA (64%). Interpretation This study shows that the current PPA classification system helps to predict underlying pathology across different cohorts and clinical settings, and suggests that age and ApoE genotype should be considered when interpreting amyloid‐β biomarkers in PPA patients. Ann Neurol 2018;84:737–748